NCI-2022-02453

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Doctors are conducting a study to test the safety and effectiveness of a new medicine called DAN-222 in treating a type of breast cancer called metastatic breast cancer. The study is a dose-escalation study, which means that patients will receive increasing amounts of DAN-222 over time to determine the maximum safe and effective dose. The study will also evaluate the pharmacology of the medicine, which means how it works in the body and how the body processes it. Patients in the study will have metastatic breast cancer. The goal of the study is to determine if DAN-222 is safe and effective in treating this type of breast cancer. By testing different doses of DAN-222 and monitoring its effects on patients, doctors hope to learn more about how the medicine works and whether it could be a new treatment option for patients with metastatic breast cancer.

​Metastatic: a cancer that has spread from its original location or organ to other parts of the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05261269

NCI-2022-02453

Clinical Trial Site: Mount Sinai

To see all available clinical trials click here.